Editor\u2019s Note:<\/strong> Tax season is here, and we have a special way for you to take advantage.<\/p>\n

On Wednesday, March 19 at 2 p.m. EST, we\u2019re going live<\/a> with our friends at Prime Corporate Services.<\/p>\n

We\u2019ll be showing you how to save money on your tax bill, plus how to write off expenses from your trading income.<\/p>\n

The event is completely FREE.<\/p>\n

Click here to sign up.<\/a><\/p>\n

– Ryan Fitzwater, Publisher<\/p>\n<\/p>\n\n

Last month, I told War Room<\/a> members I\u2019ve been looking at Moderna (MRNA) for a potential trade.<\/p>\n

But I was hesitant to recommend an outright trade for one key reason.<\/p>\n

You see\u2026 there\u2019s been a lot of blowback surrounding the pharma company over the last six months.<\/p>\n

Since COVID, Moderna got labeled a \u201cvaccine\u201d company. And with Republicans taking over the White House in January, the narrative has shifted to the negative as controversial \u201canti-vaccine activist\u201d Robert F. Kennedy Jr. assumed the role of secretary of health.<\/p>\n

But political strife aside \u2013 there are a lot of reasons to like Moderna right now.<\/p>\n

The truth is\u2026<\/p>\n

Moderna is much more than a vaccine stock.<\/p>\n

For example, it\u2019s currently working on a solution to avian flu. It\u2019s also working with Merck on a cancer vaccine. So there are multiple potential catalysts working in its favor right now.<\/p>\n

And with so much \u201canti-vaccine sentiment\u201d currently, the stock is nearing all-time lows.<\/p>\n

But that\u2019s exactly the time you should be looking at a trade.<\/p>\n

Take a look at the chart below.<\/p>\n<\/p>\n

<\/p>\n

As you\u2019ll see, Moderna was at \u201cCOVID era\u201d highs around mid 2021.<\/p>\n

Now it\u2019s fallen back to $34 a share.<\/p>\n

But with the current catalysts in avian flu and cancer vaccines working for it, I believe the stock could be in for a big move.<\/p>\n

More catalysts for MRNA<\/strong><\/p>\n

I also recently saw something that I love to see on MRNA.<\/p>\n

Earlier this month \u2013 two insiders at Moderna bought shares. Now, that\u2019s not a huge eye-opener since insiders buy stock all the time.<\/p>\n

However, in this case one insider bought $1 million worth of stock, and another insider bought $5 million worth of stock.<\/p>\n

Those are big numbers.<\/p>\n

Insiders also bought Merck and Pfizer a month ago.<\/p>\n

And here\u2019s one great thing about these pharmaceutical companies\u2026<\/p>\n

All of them are subject to headline risk \u2013 meaning you can use a two-pronged approach to trading them. For example, my colleague Bryan Bottarelli recently used a short-term trade strategy on MRNA last week. He closed a 31% winner in less than 1 trading day.<\/p>\n

But because of the long-term catalysts for Moderna, you can also use my long-play strategies as well. So there are multiple ways to play it.<\/p>\n

Action Plan: <\/strong>With a big dip in price since COVID and multiple catalysts working, I believe MRNA is a stock worth keeping on your radar.<\/p>\n

If you want to see exactly how I\u2019m playing companies like MRNA, I invite you to join Bryan and I in The War Room.<\/a> So far in 2025, we have an 81% win rate, and last week we closed 9-of-11 trades for winners despite the shaky markets.<\/p>\n

Click here to see how we navigated shaky markets like these with great success in the past.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Editor\u2019s Note: Tax season is here, and we have a special way for you to take advantage. On Wednesday, March 19 at 2 p.m. EST, we\u2019re going live with our friends at Prime Corporate Services. We\u2019ll be showing you how to save money on your tax bill, plus how to write off expenses from your … Continued<\/a><\/p>\n","protected":false},"author":3,"featured_media":17858,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1467],"tags":[],"mobile_app_tag":[],"class_list":["post-17859","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-wakeup-watchlist"],"acf":{"watchlist_for_app":null},"yoast_head":"\n